Health Care · Biological Products, (No Diagnostic Substances) · Nasdaq · CIK 1601830 · FYE Dec 31 · Prices AT CLOSE 2026-07-30 (USD) — end-of-day, never a live or intraday quote
Last $3.04Day +2.36%Mkt cap $1.4B1Y −47.7%Off 52W high −57.7%Vol (1Y) 68.0%
Daily closing price, split-adjusted to the current basis; 3y shown of 1,321 bars on file. Sampled to 240 points — every point is a real close, none averaged. Price return, not total return (dividends excluded). Source marketstack.
| Short interest40.4% of sh out |
| Days to cover6.7d |
| 13F net flow (QoQ)+2.51% |
| Top-10 13F concentration66.1% |
| Next report (est.)2026-08-06 |
Short interest is FINRA semi-monthly, settlement 2026-07-15. 13F figures are quarterly filings, period 2026-Q1 — a lower bound on true ownership.
| Sales (TTM)$66.4M |
| Earnings (TTM)-$559.8M |
| ROE−59.5% |
| Net margin−863.4% |
| ROIC−123.7% |
| Sales growth 3Y23.3% |
Screener basis: ratios from the latest reported fiscal year; Sales/Earnings are trailing twelve months in the reporting currency (USD). The P/E is a trailing FULL-YEAR P/E, not TTM. Missing lines are absent from the filings, never imputed.
| YTD−25.7% |
| 1Y−47.7% |
| 3Y−78.5% |
| 5Y−90.0% |
| Since incept. (ann.)−34.3% |
Total return through 2026-07-30 · series begins 2021-04-19. Only the windows this history actually covers are shown.
| Ann. volatility (1Y)68.0% |
| Ann. volatility (3Y)83.3% |
| Sharpe (1Y)−0.68 |
| Sharpe (3Y)−0.21 |
| Max drawdown (1Y)−58.2% |
| Max drawdown (3Y)−81.7% |
| Beta (3Y vs SPY)2.95 |
Daily simple returns, annualized; drawdown is peak-to-trough within the window. Beta is the OLS slope of monthly returns on SPY's over three years. Each figure is labeled by the window it was measured over — they are not comparable across windows.
| Manager | Shares | Value | % sh out | QoQ |
|---|---|---|---|---|
| BlackRock, Inc. | 43.2M | $133M | — | +11.1% |
| ARK Investment Management LLC | 40.2M | $123M | — | +7.8% |
| STATE STREET CORP | 28.5M | $87M | — | +12.5% |
| BAILLIE GIFFORD & CO | 23.7M | $73M | — | −0.4% |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 22.8M | $70M | — | new |
| VANGUARD CAPITAL MANAGEMENT LLC | 22.2M | $68M | — | new |
| SOFTBANK GROUP CORP. | 13.6M | $42M | — | +0.0% |
| GEODE CAPITAL MANAGEMENT, LLC | 12.3M | $38M | — | +12.3% |
Reported 13F long positions as filed for 2026-Q1 (change vs 2025-Q4). 13F covers US-listed long equity only — the sum is a LOWER BOUND on institutional ownership, never a total. % of shares outstanding not shown: no SEC cover-page share count falls within 120 days of the 2026-Q1 quarter end, so any percentage would rest on a count that cannot speak for this quarter. Holder share counts are shown as filed.
| Period end | Reported | EPS | EPS YoY | Revenue | Rev YoY |
|---|---|---|---|---|---|
| 2026-03-31 | 2026-05-06 | −$0.22 | — | $6.5M | −56.1% |
| 2025-12-31 | 2026-02-25 | — | — | $35.5M | +681.7% |
| 2025-09-30 | 2025-11-05 | −$0.36 | — | $5.2M | −80.2% |
| 2025-06-30 | 2025-08-05 | −$0.41 | — | $19.2M | +33.3% |
EPS and revenue as reported in this filer's own XBRL — our extraction of the filings, not a vendor consensus feed, and never a beat/miss claim (we carry no estimates). YoY compares the same fiscal quarter a year earlier. Next report 2026-08-06 is ESTIMATED from filing cadence (median gap 92d) — not company-confirmed.
Reportable 100%
business segments · each slice's share of TAGGED segment revenue in the latest annual filing (XBRL, as filed). Untagged revenue is excluded from the denominator, so slices need not sum to consolidated sales.
